Navigation Links
Genocea Biosciences Selected To Present Late-Breaking Oral Presentation At ICAAC 2013

CAMBRIDGE, Mass., Aug. 28, 2013 /PRNewswire/ -- Genocea Biosciences Inc., a clinical-stage company developing T cell vaccines to prevent and treat infectious diseases, announced today that its abstract describing an interim analysis of data from a Phase 1/2a clinical study of its lead candidate, GEN-003, has been selected as a late-breaking oral presentation at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013). GEN-003 is a first-in-class, investigational protein subunit vaccine for patients with moderate-to-severe herpes simplex virus type 2 (HSV-2) infection.

The abstract is entitled "Novel Therapeutic Vaccine for Genital Herpes Reduces Genital HSV-2 Shedding." Dr. Anna Wald, the Principal Investigator on the study, will present the detailed interim data during a session on Vaccine Development and Efficacy on September 12 in Denver, Colorado.

"We are pleased that ICAAC has chosen to accept our abstract given the limited number of late-breaking submissions that are selected, and believe that this acceptance reflects the quality of the study to be presented and the need for new therapeutic approaches to the HSV-2 epidemic," said Chip Clark, President and Chief Executive Officer of Genocea.

The following abstract will be presented: 
Presentation number G-1458a, "Novel Therapeutic Vaccine for Genital Herpes Reduces Genital HSV-2 Shedding," 3:00 – 5:30 p.m. MDT, September 12, 2013, Meeting Room 503.

About GEN-003
GEN-003 is a first-in-class T cell vaccine intended to reduce the viral shedding and frequency and severity of outbreaks and transmission of herpes simplex virus type 2 (HSV-2). GEN-003 is designed to induce a balanced and durable B cell (antibody) and T cell immune response.

GEN-003 includes fragments of ICP4 and gD2 antigens, as well as the proprietary adjuvant, Matrix-M™, licensed from Isconova AB. The adjuvant is a novel saponin-derived product that has demonstrated a balanced B and T cell immunostimulatory profile in previous clinical studies.

There is currently no vaccine approved to prevent or treat HSV-2. For more information about clinical studies for GEN-003 please visit For more information about GEN-003, please visit

About HSV-2
Herpes simplex virus type 2 (HSV-2), the most common cause of genital herpes, is a sexually transmitted disease that is estimated to infect more than 500 million people worldwide, and one out of six people aged 14 to 49. In the U.S., an estimated 50-60 million people are affected. HSV-2 infection can cause recurring, painful genital sores and, due to the stigma associated with this disease, can impact patients' ability to form and maintain relationships, resulting in considerable psychological distress in patients. No vaccine is currently approved to prevent or treat the disease.

About Genocea Biosciences 
Genocea Biosciences is harnessing the power of T cell immunity to develop the next generation of vaccines. T cells are increasingly recognized as a critical element of a protective immune response to a wide range of infectious disease pathogens, but are difficult to target using traditional vaccine discovery methods. Genocea is uniquely able to identify protective T cell antigens in humans exposed to a pathogen using ATLAS™, its proprietary technology platform that mimics the human immune response in the laboratory, potentially improving the effectiveness of vaccine candidates and drastically reducing the time needed to create them. Genocea's pipeline of novel T cell vaccines includes GEN-003 for HSV-2 therapy, GEN-004, a protein vaccine directed at pneumococcus that is expected to enter the clinic in the fourth quarter of 2013, and earlier-stage programs in chlamydia, HSV-2 prophylaxis and malaria.

For more information, please visit the company's website at

About Isconova
Isconova AB is a leading international vaccine adjuvant company headquartered in Uppsala, Sweden. With deep knowledge of vaccine systems, Isconova is developing vaccines independently and with partners in both the human and veterinary markets. Isconova is a subsidiary of Novavax, Inc. (NASDAQ "NVAX"). For more information on Isconova:

For information contact:
Jessica Rowlands 

For investor relations:
Bob Farrell

SOURCE Genocea Biosciences Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Industry Veteran Katrine Bosley Joins Genocea Biosciences Board Of Directors
2. Genocea Publishes Preclinical Data For Investigational Vaccine Candidate For HSV-2
3. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
4. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
5. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
6. Neurocrine Biosciences Reports First Quarter 2012 Results
7. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
8. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
9. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
10. 3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
11. Sofie Biosciences receives $1M Phase II SBIR grant from the DOE
Post Your Comments:
(Date:11/26/2015)... 26, 2015 ... of the  "2016 Future Horizons and ... Drug Monitoring (TDM) Market: Supplier Shares, ... Opportunities"  report to their offering.  ... the addition of the  "2016 Future ...
(Date:11/26/2015)... 26, 2015 ... of the  "2016 Future Horizons and ... Surface Marker Testing Market: Supplier Shares, ... their offering.  --> ... the  "2016 Future Horizons and Growth ...
(Date:11/25/2015)... Nov. 25, 2015  Linden Care, LLC, a retail ... outcomes for patients suffering from chronic pain, said today ... Temporary Restraining Order (TRO) enjoining Express Scripts from unilaterally ... --> --> The ... its legal options. --> ...
Breaking Medicine Technology:
(Date:11/26/2015)... San Antonio, TX (PRWEB) , ... November 26, 2015 , ... ... accomplishment! On November 19, 2015, our surgeons performed their 6,000th free flap breast ... Ledoux , “We wake up every day excited to rebuild lives and it’s an ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... than those found on mammography, according to a study published online in the ... not seen on mammography may necessitate a change in treatment. , Breast MRI ...
(Date:11/25/2015)... ... November 25, 2015 , ... TyloHelo Inc , ... accessories. , Sauna accessories help improve the bather experience in the sauna, and ... styles for the purist looking for simplicity in design to accessories that encourage ...
(Date:11/25/2015)... , ... November 25, 2015 , ... According to an ... robot is being more and more widely heralded as a breakthrough for performing hernia ... method has over traditional laparoscopic surgery is that it can greatly reduce the pain ...
(Date:11/25/2015)... ... , ... The McHenry County law firm of Botto Gilbert Lancaster, PC ... J. Botto and Alex C. Wimmer. Attorneys Botto and Wimmer represented the claimant David ... 130884WC. , According to court documents, Adcock testified that on May 10, 2010 he ...
Breaking Medicine News(10 mins):